News and Announcements
Walker Capital Raises $250k as Round 1 of their Capital Raise Closes
- Published August 13, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Walker Capital announce the completion of Round 1 of their capital raise
- They have now commenced Round 2 of the capital raise
- Round 1 funds will be used to launch their marketing campaign and development of their investment platform
Walker Capital are excited to announce the completion of Round 1 of their capital raise. Within hours of launching the offer, they have achieved their goal, $250,000. Walker Capital have now commenced Round 2 of the capital raise.
The Round 1 funds will be used to launch their marketing campaign including a complete inbound marketing strategy. Funds will also be used for the development of our investment platform and integration with our broker/counter parties.
They send their thanks to the cornerstone investor for their confidence in the Company; within 24 hours Walker Capital have opened and closed their first round subscription and are excited to have achieved a notional 100% increase for their cornerstone investor with the opening of Round 2.
About Walker Capital
Walker Capital offers a managed discretionary account (MDA) service, specialising in rules-based trading of derivatives. With expert guidance from its seasoned investment managers, Walker Capital develops and manages sophisticated currency related trading models suitable for a variety of investors and investment strategies. The Company’s investment managers only trade in markets in which they believe they have a statistical edge and is based on mathematical models derived from extensive statistical research and study.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
